Mrs. Denise Lee Feirer, SLP Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 600 E Elm St, Abbotsford, WI 54405 Phone: 715-223-8051 |
Valeri Scheps Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1769 4 1/2 St, Almena, WI 54805 Phone: 715-296-0961 |
Thomas Lee Hintgen, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1490 Rivers Edge Trl, Altoona, WI 54720 Phone: 715-828-2368 Fax: 715-839-7796 |
Lesa Cramer, MA/CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1451 Bluestem Blvd Ste E, Altoona, WI 54720 Phone: 715-727-5621 |
Megan Ziemann, M.S. SLP-CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2512 New Pine Dr, Altoona, WI 54720 Phone: 715-833-0400 Fax: 715-833-0546 |
Kelly Eaton, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1451 Bluestem Blvd Ste E, Altoona, WI 54720 Phone: 715-829-0223 |
Erin J Fredericks, SLP MSE CCCSLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 505 Keller Ave S, Amery, WI 54001 Phone: 715-268-6900 Fax: 715-268-6895 |
Mrs. Rosemma Devries Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 265 Griffin St E, Amery, WI 54001 Phone: 715-268-2680 |
Mary Louise Kramlinger, M.S. CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 265 Griffin St E, Amery, WI 54001 Phone: 715-268-8000 |
Ms. Tiffany A. Sinn, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 505 Keller Ave S, Amery, WI 54001 Phone: 715-268-6900 |
Tiffany Anderson Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 220 Scholl Ct, Amery, WI 54001 Phone: 715-268-7107 |
Stacey R Cunningham, SLP MSE CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 505 Keller Ave S, Amery, WI 54001 Phone: 715-268-6900 Fax: 715-268-6895 |
Ms. Susan Marie Carlin, MSE, CFY-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 505 Keller Ave S, Amery, WI 54001 Phone: 715-268-6900 Fax: 715-268-6895 |
Annika Grace Fox, M.S., CF-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 112 E 5th Ave, Antigo, WI 54409 Phone: 715-623-2331 |
Jesse Daniel Hoffmeister, M.S., SLP Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: N2250 W Rollwood Rd, Antigo, WI 54409 Phone: 715-216-0714 |
Jessica L Pipkorn, M.S. CFY-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 729 Park St, Antigo, WI 54409 Phone: 715-623-2356 |
Carol L. Mcdougal, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 230 E North Ave, Antigo, WI 54409 Phone: 715-623-9101 |
Stephanie Krautkramer Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 112 E 5th Ave, Antigo, WI 54409 Phone: 715-623-2331 |
Jennifer Marie Larsen-fritcher, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1225 Langlade Rd, Antigo, WI 54409 Phone: 715-623-9449 Fax: 715-623-9425 |
Mrs. Debora Ann Dabel, MS CCC- SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 729 Park St, Antigo, WI 54409 Phone: 715-623-2356 |
News Archive
Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint.
In the face of a global pandemic, thousands of K-12 school districts from Los Angeles to New York City and many cities in between announced closures in recent days.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 7,912,000 shares of its common stock, including 1,032,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. Net proceeds were approximately $44.4 million after deducting underwriting discounts and estimated offering expenses. Jefferies & Company, Inc. acted as the sole book-running manager and Canaccord Genuity Inc. acted as co-lead manager for the offering.
Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).
› Verified 1 days ago